secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXICURE, INC. (XCUR)
CIK:        0001698530
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001628280-24-003304
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exicure licenses cavrotolimod patents to Bluejay for hepatitis treatment
------------------------------------------------------------------------

- Bluejay receives exclusive license in hepatitis field to Exicure's patents; small upfront payment made.
- Exicure eligible for modest royalties on future net sales of licensed technology.
- Exicure responsible for prosecution and maintenance of licensed patents.
- Cavrotolimod historically developed for oncology; repurposed for hepatitis by Bluejay.
- Bluejay is a private clinical-stage biopharma focused on viral and liver diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1698530/000162828024003304/0001628280-24-003304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1698530/000162828024003304/xcur-20240205.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-003304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer